Assessment of myocardial viability by cardiovascular magnetic resonance

Echocardiography

Volumn 22, Issue 2, 2005, Pages 179-193

  Lloyd, Steven G ^a   Gupta, Himanshu ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Heart failure; Hibernation; Ischemic heart disease; Magnetic resonance imaging; Magnetic resonance spectroscopy; Myocardial infarction; Nuclear magnetic resonance; Revascularization

Indexed keywords

CONTRAST MEDIUM; DOBUTAMINE; FLUORODEOXYGLUCOSE F 18; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERIDOL; TECHNETIUM 99M; THALLIUM 201;

CONTRAST ENHANCEMENT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MYOCARDIAL HIBERNATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STANDARD; STUNNED HEART MUSCLE;

CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MANGANESE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL STUNNING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 13444269081     PISSN: 07422822     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0742-2822.2005.04033.x     Document Type: Review

References (82)

1. Wijns W, Vatner SF, Camici PG: Hibernating myocardium. N Engl J Med 1998;339:173-181.
2. Schulz R, Heusch G: Hibernating myocardium. Heart 2000;84:587-594.
3. Pasquet A, Robert A, D'Hondt AM, et al: Prognostic value of myocardial ischemia and viability in patients with chronic left ventricular ischemic dysfunction. Circulation 1999;100:141-148.
4. Kaul S: There may be more to myocardial viability than meets the eye. Circulation 1995;92:2790-2793.
5. Beller GA, Bonow RO, Fuster VU, et al: ACC revised recommendations for training in adult cardiovascular medicine core cardiology training II (COCATS 2)(revision of the 1995 COCATS training statement). J Am Coll Cardiol 2002;39:1242-1246.
6. Schoen FJ: Chapter 13: The heart. In Cotran RS, Kumar V, Collins T (eds): Robbins Pathologic Basis of Disease. Philadelphia, W. B. Saunders Company, 1999, p. 558.
7. Perrone-Filardi P, Bacharach SL, Dilsizian V, et al: Metabolic evidence of viable myocardium in regions with reduced wall thickness and absent wall thickening in patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 1992;20:161-168.
8. Baer FM, Voth E, Schneider CA, et al: Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Circulation 1995;91:1006-1015.
9. Oshinski JN, Han HC, Ku DN, et al: Quantitative prediction of improvement in cardiac function after revascularization with MR imaging and modeling: Initial results. Radiology 2001;221:515-522.
10. Afridi I, Kleiman NS, Raizner AE, et al: Dobutamine echocardiography in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation 1995;91:663-670.
11. Hundley WG, Morgan TM, Neagle CM, et al: Magnetic resonance imaging determination of cardiac prognosis. Circulation 2002;106:2328-2333.
12. Dendale PA, Franken PR, Waldman GJ, et al: Low-dosage dobutamine magnetic resonance imaging as an alternative to echocardiography in the detection of viable myocardium after acute infarction. Am Heart J 1995;130:134-140.
13. Gunning MG, Anagnostopoulos C, Knight CJ, et al: Comparison of 201Tl, 99mTc-tetrofosmin, and dobutamine magnetic resonance imaging for identifying hibernating myocardium. Circulation 1998;98:1869-1874.
14. Gunning MG, Kaprielian RR, Pepper J, et al: The histology of viable and hibernating myocardium in relation to imaging characteristics. J Am Coll Cardiol 2002;39:428-435.
15. Dendale P, Franken PR, Holman E, et al: Validation of low-dose dobutamine magnetic resonance imaging for assessment of myocardial viability after infarction by serial imaging. Am J Cardiol 1998;82:375-377.
16. Zamorano J, Delgado J, Almeria C, et al: Reason for discrepancies in identifying myocardial viability by thallium-201 redistribution, magnetic resonance imaging, and dobutamine echocardiography. Am J Cardiol 2002;90:455-459.
17. Sandstede J, Bertsch G, Beer M, et al: Detection of myocardial viability by low-dose dobutamine cine MR imaging. Magn Reson Imaging 1999;17:1437-1443.
18. Baer FM, Theissen P, Schneider CA, et al: Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol 1998;31:1040-1048.
19. Baer FM, Theissen P, Crnac J, et al: Head to head comparison of dobutamine-transoesophageal echocardiography and dobutamine-magnetic resonance imaging for the prediction of left ventricular functional recovery in patients with chronic coronary artery disease. Eur Heart J 2000;21:981-991.
20. Hundley WG, Hamilton CA, Thomas MS, et al: Utility of fast cine magnetic resonance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography. Circulation 1999;100:1697-1702.
21. Zerhouni EA, Parish DM, Rogers WJ, et al: Human heart: Tagging with MR imaging-a method for non-invasive assessment of myocardial motion. Radiology 1988;169:59-63.
22. Garot J, Bluemke DA, Osman NF, et al: Fast determination of regional myocardial strain fields from tagged cardiac images using harmonic phase MRI. Circulation 2000;101:981-988.
23. Clark NR, Reichek N, Bergey P, et al: Circumferential myocardial shortening in the normal human left ventricle. Assessment by magnetic resonance imaging using spatial modulation of magnetization. Circulation 1991;84:67-74.
24. McVeigh ER, Zerhouni EA: Noninvasive measurement of transmural gradients in myocardial strain with MR imaging. Radiology 1991;180:677-683.
25. Geskin G, Kramer CM, Rogers WJ, et al: Quantitative assessment of myocardial viability after infarction by dobutamine magnetic resonance tagging. Circulation 1998;98:217-223.
26. Kramer CM, Malkowski MJ, Mankad S, et al: Magnetic resonance tagging and echocardiographic response to dobutamine and functional improvement after reperfused myocardial infarction. Am Heart J 2002;143:1046-1051.
27. Schalla S, Klein C, Paetsch I, et al: Real-time MR image acquisition during high-dose dobutamine hydrochloride stress for detecting left ventricular wall-motion abnormalities in patients with coronary arterial disease. Radiology 2002;224:845-851.
28. Garot J, Unterseeh T, Teiger E, et al: Magnetic resonance imaging of targeted catheter-based implantation of myogenic precursor cells into infarcted left ventricular myocardium. J Am Coll Cardiol 2003;41:1841-1846.
29. Rehwald WG, Fieno DS, Chen EL, et al: Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 2002;105:224-229.
30. de Roos A, van Rossum AC, van der Wall E, et al: Reperfused and nonreperfused myocardial infarction: Diagnostic potential of Gd-DTPA-enhanced MR imaging. Radiology 1989;172:717-720.
31. Van Rossum AC, Visser FC, Van Eenige MJ, et al: Value of gadolinium-diethylene-triamine pentaacetic acid dynamics in magnetic resonance imaging of acute myocardial infarction with occluded and reperfused coronary arteries after thrombolysis. Am J Cardiol 1990;65:845-851.
32. McNamara MT, Tscholakoff D, Revel D, et al: Differentiation of reversible and irreversible myocardial injury by MR imaging with and without gadolinium-DTPA. Radiology 1986;158:765-769.
33. Brady TJ, Goldman MR, Pykett IL, et al: Proton nuclear magnetic resonance imaging of regionally ischemic canine hearts: Effect of paramagnetic proton signal enhancement. Radiology 1982;144:343-347.
34. Wesbey GE, Higgins CB, McNamara MT, et al: Effect of gadolinium-DTPA on the magnetic relaxation times of normal and infarcted myocardium. Radiology 1984;153:165-169.
35. Rehr RB, Peshock RM, Malloy CR, et al: Improved in vivo magnetic resonance imaging of acute myocardial infarction after intravenous paramagnetic contrast agent administration. Am J Cardiol 1986;57:864-868.
36. Tscholakoff D, Higgins CB, Sechtem U, et al: Occlusive and reperfused myocardial infarcts: Effect of Gd-DTPA on ECG-gated MR imaging. Radiology 1986;160:515-519.
37. Lima JA, Judd RM, Bazille A, et al: Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. Circulation 1995;92:92.
38. Kim RJ, Chen EL, Lima JA, et al: Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation 1996;94:3318-3326.
39. Schulz-Menger J, Gross M, Messroghli D, et al: Cardiovascular magnetic resonance of acute myocardial infarction at a very early stage. J Am Coll Cardiol 2003;42:513-518.
40. Ricciardi MJ, Wu E, Davidson CJ, et al: Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001;103:2780-2783.
41. Wu E, Judd RM, Vargas JD, et al: Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001;357:21-28.
42. Fieno DS, Kim RJ, Chen EL, et al: Contrast-enhanced magnetic resonance imaging of myocardium at risk: Distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 2000;36:1985-1991.
43. Oshinski JN, Yang Z, Jones JR, et al: Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. Circulation 2001;104:2838-2842.
44. Saeed M, Lund G, Wendland WF, et al: Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction with necrosis-specific and extracellular nonspecific contrast media. Circulation 2001;103:871-876.
45. Judd RM, Lugo-Olivieri CH, Arai M, et al: Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation 1995;92:1902-1910.
46. Kim RJ, Fieno DS, Parrish TB, et al: Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992-2002.
47. Gerber BL, Rochitte CE, Bluemke DA, et al: Relation between Gd-DTPA contrast enhancement and regional inotropic response in the periphery and center of myocardial infarction. Circulation 2001;104:998-1004.
48. Hillenbrand HB, Kim RJ, Parker MA, et al: Early assessment of myocardial salvage by contrast-enhanced magnetic resonance imaging. Circulation 2000;102:1678-1683.
49. Wagner A, Mahrholdt H, Holly TA, et al: Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: An imaging study. Lancet 2003;361:374-379.
50. Simonetti OP, Kim RJ, Fieno DS, et al: An improved MR imaging technique for the visualization of myocardial infarction. Radiology 2001;218:215-223.
51. Arai AE, Ingkanisorn WP, Rhoads KL, et al: User dependent parameters can markedly influence apparent infarct size on MRI. Circulation 2002;106(Suppl II):II-388.
52. Mahrholdt H, Wagner A, Parker M, et al: Relationship of contractile function to transmural extent of infarction in patients with chronic coronary artery disease. J Am Coll Cardiol 2003;42:505-512.
53. Sandstede JJ, Lipke C, Beer M, et al: Analysis of first-pass and delayed contrast-enhancement patterns of dysfunctional myocardium on MR imaging: Use in the prediction of myocardial viability. AJR Am J Roentgenol 2000;174:1737-1740.
54. Gerber BL, Garot J, Bluemke DA, et al: Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation 2002;106:1083-1089.
55. Kim RJ, Wu E, Rafael A, et al: The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-1453.
56. Choi KM, Kim RJ, Gubernikoff G, et al: Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation 2001;104:1101-1107.
57. Beek AM, Kuhl HP, Bondarenko O, et al: Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. J Am Coll Cardiol 2003;42:895-901.
58. Rogers WJ Jr, Kramer CM, Geskin G, et al: Early contrast-enhanced MRI predicts late functional recovery after reperfused myocardial infarction. Circulation 1999;99:744-750.
59. Kramer CM, Rogers WJ Jr, Mankad S, et al: Contractile reserve and contrast uptake pattern by magnetic resonance imaging and functional recovery after reperfused myocardial infarction. J Am Coll Cardiol 2000;36:1835-1840.
60. Ingkanisorn WP, Rhoads KL, Kellman P, et al: MRI delayed hyperenhancement overestimates acute myocardial infarction size in humans. Circulation 2002;106(Suppl II):II-389.
61. Abdel-Aty H, Kumar A, Schulz-Menger J, et al: Acute and chronic myocardial infarcts have different contrast washout kinetics in 'delayed enhancement' MRI. Circulation 2002;106(Suppl II):II-388.
62. Doyle M, Ripple J, Yamrozik J, et al: Regions of delayed hyperenhancement can demonstrate long term improved function. Circulation 2002;106(Suppl II):II-389.
63. Doyle M, Ripple J, Yamrozik J, et al: Predictive value of early delayed hyperenhancement: Post revascularization. Circulation 2002;106(Suppl II):II-159.
64. Bello D, Shah DJ, Farah GM, et al: Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 2003;108:1945-1953.
65. Fedele F, Montesano T, Ferro-Luzzi M, et al: Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction: Role of magnetic resonance imaging. Am Heart J 1994;128:484-489.
66. Ramani K, Judd RM, Holly TA: Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation 1998;98:2687-2694.
67. Klein C, Nekolla SG, Bengel FM, et al: Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: Comparison with positron emission tomography. Circulation 2002;105:162-167.
68. Kühl HP, Beek AM, van der Weerdt AP, et al: Myocardial viability in chronic ischemic heart disease: Comparison of contrast-enhanced magnetic resonance imaging with (18)F-fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2003;41:1341-1348.
69. Knuesel PR, Nanz D, Wyss C, et al: Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance: Relation to functional outcome after revascularization. Circulation 2003;108:1095-1100.
70. Moran GR, Thornhill RE, Sykes J, et al: Myocardial viability imaging using Gd-DTPA: Physiological modeling of infarcted myocardium, and impact on injection strategy and imaging time. Magn Reson Med 2002;48:791-800.
71. Flacke S, Allen JS, Chia JM, et al: Characterization of viable and nonviable myocardium at MR imaging: Comparison of gadolinium-based extracellular and blood pool contrast materials versus manganese-based contrast materials in a rat myocardial infarction model. Radiology 2003;226:731-738.
72. Kim RJ, Lima JA, Chen EL, et al: Fast 23Na magnetic resonance imaging of acute reperfused myocardial infarction. Potential to assess myocardial viability. Circulation 1997;95:1877-1885.
73. Horn M, Weidensteiner C, Scheffer H, et al: Detection of myocardial viability based on measurement of sodium content: A (23)Na-NMR study. Magn Reson Med 2001;45:756-764.
74. Sandstede JJW, Pabst T, Beer M, et al: Assessment of myocardial infarction in humans with 23Na MR imaging: Comparison with cine MR imaging and delayed contrast enhancement. Radiology 2001;221:222-228.
75. Forder JR, Pohost GM: Cardiovascular nuclear magnetic resonance: Basic and clinical applications. J Clin Invest 2003;111:1630-1639.
76. Bottomley PA, Weiss RG: Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium. Lancet 1998;351:714-718.
77. Pohost GM. Is 31P-NMR spectroscopic imaging a viable approach to assess myocardial viability? Circulation 1995;92:9-10.
78. Yabe T, Mitsunami K, Inubushi T, et al: Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. Circulation 1995;92:15-23.
79. Meininger M, Landschutz W, Beer M, et al: Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy. Magn Reson Med 1999;41:657-663.
80. Beer M, Seyfarth T, Sandstede J, et al: Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 2002;40:1267-1274.
81. Weiss CR, Aletras AH, London JF, et al: Stunned, infarcted, and normal myocardium in dogs: Simultaneous differentiation by using gadolinium-enhanced cine MR imaging with magnetization transfer contrast. Radiology 2003;226:723-730.
82. Perin EC, Silva GV, Sarmento-Leite R, et al: Assessing myocardial viability and infarct transmurality with left ventricular electromechanical mapping in patients with stable coronary artery disease: Validation by delayed-enhancement magnetic resonance imaging. Circulation 2002;106:957-961.